Encrypted | Login
HyTEC 2114 - Organs at Risk Considerations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma? (2018)

Category: HyTEC

Data were pooled from published reports to analyze dosimetric and clinical predictors of radiation-induced lung toxicity after thoracic stereotactic body radiation therapy. Most reviewed studies report safe treatment for mean combined lung dose &lge;8 Gy (3-5 fractions) and percent total combined lung V20 &lge; 10%-15%. Interstitial lung disease is a particular risk factor. More detailed dosimetric and endpoint reporting are needed to facilitate future development of accurate quantitative models of radiation-induced lung toxicity.

Supplemental Materials 1

International Journal of Radiation Oncology*Biology*Physics

Feng-Ming (Spring) Kong, MD, PhD, Vitali Moiseenko, PhD, Jing Zhao, MD, Michael T. Milano, MD, PhD, Ling Li, MD, PhD, Andreas Rimner, MD, Shiva Das, PhD, X. Allen Li, PhD, Moyed Miften, PhD, ZhongXing Liao, MD, Mary Martel, PhD, Soren M. Bentzen, PhD, DMSc, Andrew Jackson, PhD, Jimm Grimm, PhD, Lawrence B. Marks, MD, and Ellen Yorke, PhD

I Disagree
I Agree

Show list of all AAPM HyTec Reports »